1. Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B).
Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B). Concomitant plasma trough liraglutide concentrations (C) (only liraglutide groups are shown) and dose-corrected plasma trough liraglutide concentrations (D) (only liraglutide groups are shown). Data are means ± SE (A–C) and estimated geometric means with 95% CIs (D) based on data from the PP population. Asterisks (*) in D indicate significance (P < 0.05).
Thomas Idorn et al. Dia Care 2016;39:
©2016 by American Diabetes Association